A Systems Approach to Immunotherapy Biomarker Identification Within

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04544046` - Supportive Oncology Care At Home RCT	N/A
Not yet recruiting	`NCT04555304` - Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy	Phase 2
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Completed	`NCT04099641` - An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients	Phase 2
Not yet recruiting	`NCT05431738` - Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)	N/A
Recruiting	`NCT04385641` - Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer	N/A
Completed	`NCT03165994` - APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers	Phase 2
Active, not recruiting	`NCT03279237` - A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers	Phase 1
Completed	`NCT03321630` - A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies	Phase 2
Completed	`NCT02853474` - Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy	Phase 3
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03983954` - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT06138223` - The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)	N/A
Active, not recruiting	`NCT03647969` - Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT05122091` - Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma	Phase 2
Completed	`NCT03720678` - A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies	Phase 1
Not yet recruiting	`NCT06356311` - A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)	Phase 3
Completed	`NCT02317991` - Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer	Phase 2
Completed	`NCT02013154` - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab	Phase 1
Terminated	`NCT05395052` - FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1

NCT number	NCT05338060
Study type	Observational
Source	Inova Health Care Services
Contact	Keary Janet, BS
Phone	571-472-0224
Email	keary.janet@inova.org
Status	Recruiting
Phase
Start date	January 26, 2022
Completion date	January 30, 2025

A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer — BAISIC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms